Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 2
2002 1
2003 5
2004 2
2005 6
2006 1
2007 2
2008 5
2009 13
2010 11
2011 5
2012 13
2013 13
2014 10
2015 9
2016 8
2017 5
2018 3
2019 10
2020 5
2021 11
2022 5
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Results by year

Filters applied: . Clear all
Page 1
Vogt-Koyanagi-Harada disease.
Joye A, Suhler E. Joye A, et al. Among authors: suhler e. Curr Opin Ophthalmol. 2021 Nov 1;32(6):574-582. doi: 10.1097/ICU.0000000000000809. Curr Opin Ophthalmol. 2021. PMID: 34545845 Review.
Adalimumab in Patients with Active Noninfectious Uveitis.
Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB. Jaffe GJ, et al. Among authors: suhler eb. N Engl J Med. 2016 Sep 8;375(10):932-43. doi: 10.1056/NEJMoa1509852. N Engl J Med. 2016. PMID: 27602665 Free article. Clinical Trial.
Rituximab for Ocular Inflammatory Disease.
Cunningham ET Jr, Ng C, Suhler EB, Smit DP. Cunningham ET Jr, et al. Among authors: suhler eb. Ocul Immunol Inflamm. 2022 Aug;30(6):1300-1302. doi: 10.1080/09273948.2022.2141034. Ocul Immunol Inflamm. 2022. PMID: 36379016 No abstract available.
Drug-induced uveitis.
Shifera AS, Kopplin L, Lin P, Suhler EB. Shifera AS, et al. Among authors: suhler eb. Int Ophthalmol Clin. 2015 Spring;55(2):47-65. doi: 10.1097/IIO.0000000000000059. Int Ophthalmol Clin. 2015. PMID: 25730619 Review. No abstract available.
Drug-induced inflammation in patients on TNFα inhibitors.
Cunningham ET Jr, Pasadhika S, Suhler EB, Zierhut M. Cunningham ET Jr, et al. Among authors: suhler eb. Ocul Immunol Inflamm. 2012 Feb;20(1):2-5. doi: 10.3109/09273948.2011.644383. Ocul Immunol Inflamm. 2012. PMID: 22324894 No abstract available.
Incidence of and Risk Factors for Cataract in Anterior Uveitis.
Papaliodis GN, Rosner BA, Dreger KA, Fitzgerald TD, Artornsombudh P, Kothari S, Gangaputra SS, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Bhatt NP, Foster CS, Jabs DA, Pak CM, Ying GS, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group. Papaliodis GN, et al. Among authors: suhler eb. Am J Ophthalmol. 2023 Oct;254:221-232. doi: 10.1016/j.ajo.2023.06.021. Epub 2023 Jul 5. Am J Ophthalmol. 2023. PMID: 37414328
The future of uveitis treatment.
Lin P, Suhler EB, Rosenbaum JT. Lin P, et al. Among authors: suhler eb. Ophthalmology. 2014 Jan;121(1):365-376. doi: 10.1016/j.ophtha.2013.08.029. Epub 2013 Oct 26. Ophthalmology. 2014. PMID: 24169255 Free PMC article. Review.
Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality.
Kempen JH, Newcomb CW, Washington TL, Foster CS, Sobrin L, Thorne JE, Jabs DA, Suhler EB, Rosenbaum JT, Sen HN, Levy-Clarke GA, Nussenblatt RB, Bhatt NP, Lowder CY, Goldstein DA, Leiderman YI, Acharya NR, Holland GN, Read RW, Dunn JP, Dreger KA, Artornsombudh P, Begum HA, Fitzgerald TD, Kothari S, Payal AR, Daniel E, Gangaputra SS, Kaçmaz RO, Liesegang TL, Pujari SS, Khachatryan N, Maghsoudlou A, Suga HK, Pak CM, Helzlsouer KJ, Buchanich JM; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group. Kempen JH, et al. Among authors: suhler eb. Ophthalmology. 2023 Dec;130(12):1258-1268. doi: 10.1016/j.ophtha.2023.07.023. Epub 2023 Jul 26. Ophthalmology. 2023. PMID: 37499954
Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Suhler EB, Jaffe GJ, Fortin E, Lim LL, Merrill PT, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Van Calster J, Cimino L, Adan A, Goto H, Kaburaki T, Kramer M, Vitale AT, Kron M, Song AP, Liu J, Pathai S, Douglas KM, Schlaen A, Muccioli C, Van Velthoven MEJ, Zierhut M, Rosenbaum JT. Suhler EB, et al. Ophthalmology. 2021 Jun;128(6):899-909. doi: 10.1016/j.ophtha.2020.10.036. Epub 2020 Nov 3. Ophthalmology. 2021. PMID: 33157077 Free article. Clinical Trial.
Risk of Cataract in Intermediate Uveitis.
Minkus CL, Pistilli M, Dreger KA, Fitzgerald TD, Payal AR, Begum H, Kaçmaz RO, Jabs DA, Nussenblatt RB, Rosenbaum JT, Levy-Clarke GA, Sen HN, Suhler EB, Thorne JE, Bhatt NP, Foster CS, Buchanich JM, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group. Minkus CL, et al. Among authors: suhler eb. Am J Ophthalmol. 2021 Sep;229:200-209. doi: 10.1016/j.ajo.2021.02.032. Epub 2021 Mar 10. Am J Ophthalmol. 2021. PMID: 33713679 Free PMC article.
135 results